Jan 30, 2020 / 03:00PM GMT
Severin Schwan - Roche Holding AG - CEO & Executive Director
Good afternoon. Great to be back in London for our full year briefing. Let me get right into the numbers, which we shared with you already. This morning, you have seen group sales up by 9%, in local currencies 8%, at constant rates. Core EPS growing at a stronger rate at 13%. And on that basis, we propose to increase the dividend to CHF 9.
On a divisional basis, a very strong result on the Pharma side, entirely driven by the newly launched medicines. I will come back to that in a moment. On the Diagnostics side, solid, more moderate growth at 3%. I'll get back to that in a moment as well.
Now if you look here on the quarterly sales development, you see a 6% sales growth after a very strong third quarter. And there are really 2 reasons why sales growth has come down in the fourth quarter. On the one hand, we do feel the impact of the biosimilars now in the U.S. So finally, they have entered. And on the other hand, we took a decision to take down inventories in China, actually for both divisions, for Diagnostics and for
Full Year 2019 Roche Holding AG Earnings Call Transcript
Jan 30, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers